To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).

Start Date01 Feb 2026

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

NCT07044700

/ Not yet recruitingNot Applicable

Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China

This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
The primary objective is to compare the risk of the composite outcome of cardiovascular (CV) death or hospitalisation for heart failure (HHF) in heart failure with reduced ejection fraction (HFrEF) patients initiating Jardiance with propensity score (PS) matched HFrEF patients initiating guideline-recommended non-sodium-glucose cotransporter-2 inhibitors (SGLT2i) medications (angiotensin-converting-enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), betablockers, and mineralocorticoid receptor antagonist (MRA)) in China, measured by the hazard ratio of the two groups.

Start Date31 Jan 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06625073

/ Not yet recruitingPhase 4IIT

Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients

Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and/or diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population.
In this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.

Start Date02 Jan 2026

Sponsor / Collaborator

VA Office of Research and Development

100 Clinical Results associated with Empagliflozin

100 Translational Medicine associated with Empagliflozin

100 Patents (Medical) associated with Empagliflozin

4,296

Literatures (Medical) associated with Empagliflozin

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-utility analysis of empagliflozin for heart failure in the Philippines

Article

Author: Llanes, Elmer Jasper ; Salvador, Dante ; Añonuevo, John ; Montilla, Precious Juzenda ; Ong-Garcia, Helen ; Encarnacion, Patrick James ; Taneo, Mary Joy ; Orolfo, Diana Dalisay ; Aquino, Camilo Oliver ; Permejo, Chito ; Villanueva, Anthony Russell ; Cunanan, Elaine

AIMS:

Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.

METHODS:

Using a Markov model, we predicted lifetime costs and clinical outcomes associated with treating HF in the Philippine setting. We used estimates of treatment efficacy, event probabilities, and derivations of utilities from the EMPEROR trials. Costs were derived from hospital tariffs and expert consensus. Separate analyses were performed for patients with left ventricular EF > 40%, categorized under mid-range ejection fraction or preserved ejection fraction (HFmrEF/HFpEF), and patients with left EF ≤ 40%, categorized under HF with reduced ejection fraction (HFrEF).

RESULTS:

Our model predicted an average of 0.09 quality-adjusted life year (QALY) gains among HFmrEF/HFpEF patients and HFrEF patients when empagliflozin was compared to SoC. The addition of empagliflozin in the treatment results in a discounted incremental lifetime cost of PHP 62,692 (USD 1,129.99) and PHP 17,215 (USD 308.67) for HFmrEF/HFpEF and HFrEF, respectively. The incremental cost-effectiveness ratio (ICER) of empagliflozin is PHP 198,270 (USD 3,570.72)/QALY and PHP 742,604 (USD 13,385.08)/QALY for HFrEF and HFmrEF/HFpEF, respectively.

LIMITATIONS:

This study employed parameters derived from short-term clinical trial data, alongside metrics representative of Asian populations, which are not specific to the Philippine cohort.

CONCLUSIONS:

Adding empagliflozin to the SoC in comparison to the SoC is associated with improved clinical outcomes and quality-of-life, at additional costs for both HFrEF and HFmrEF/HFpEF.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand

Article

Author: Satirapoj, Bancha ; Susantitaphong, Paweena ; Singhan, Wanchana ; Ophascharoensuk, Vuddhidej ; Dilokthornsakul, Piyameth

OBJECTIVE:

The prevalence of chronic kidney disease (CKD) in Thailand is high and kidney disease progression remains a problem. Empagliflozin has been known to be used to slow CKD progression, but its accessibility remains limited. This study aimed to assess the cost-utility of empagliflozin for CKD progression in Thailand.

METHODS:

A state-transition model was developed consisting of eight health states: five eGFR health states (G2, G3a, G3b, G4, and G5), dialysis, kidney transplantation, and death. Empagliflozin 10 mg was assessed as an add-on treatment to standard of care (SoC). The efficacy of empagliflozin was derived from the EMPA-KIDNEY trial, while other inputs were obtained from a comprehensive literature review. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) was calculated. A probabilistic sensitivity analysis (PSA) was performed to explore uncertainties.

RESULTS:

Empagliflozin could improve QALYs by 0.62 and 0.71 for patients with CKD without and with diabetes mellitus (DM) compared with SoC, respectively. However, it required higher total lifetime costs of 77,966 Thai baht (THB) and 59,454 THB for patients with CKD without and with DM, respectively. The ICER for CKD without DM was 126,201 THB/QALY, while the ICER for CKD with DM was 83,473 THB/QALY. The PSA indicated that empagliflozin had a 64.00% probability of being cost-effective for CKD without DM and an 89.18% probability for CKD with DM.

LIMITATIONS:

An important limitation was that the treatment effects of empagliflozin were derived from the EMPA-KIDNEY, which was conducted in DM patients and assumed to be the same for non-DM patients because of the limited evidence in non-DM patients.

CONCLUSION:

At the current willingness-to-pay threshold of 160,000 THB/QALY, empagliflozin was cost-effective for treating patients with CKD without or with DM.

01 Dec 2025·Current Neurology and Neuroscience Reports

The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

Review

Author: Moustafa, Bayan ; Trifan, Gabriela

PURPOSE OF REVIEW:

Diabetes is a well-established risk factor for stroke. Understanding the pathophysiology of this connection is crucial to implementing appropriate prevention strategies. Lately, there has been a paradigm shift in the care of individuals with diabetes toward the use of glucose-lowering medications with potential cardiovascular, cerebrovascular or cardiorenal benefits. The aim of this article is to provide a critical analysis of the role of diabetes in cerebrovascular disease and current evidence and recommendations for the use of glucose-lowering medication with particular focus on the sodium glucose cotransporter-2 inhibitor (SGLT2i) class.

RECENT FINDINGS:

Intensive glycemic control in individuals with diabetes reduces the risk of microvascular complications, but there is less clear evidence for decreasing risk of macrovascular events (e.g., stroke). A multifaceted management of diabetes addressing healthy lifestyle practices, glycemic control, and optimization of other cardiovascular risk factors is highly recommended. SGLT2i are the latest class of antihyperglycemic agents available for diabetes management. Canagliflozin and empagliflozin are associated with reduction in major adverse cardiovascular events (MACE). Dapagliflozin did not reduce the rate of MACE but is associated with reduction in heart-failure related death and hospitalization and has the potential to decrease dementia risk. Ertugliflozin decreases rates of hospitalization related to heart failure however it was non-inferior to placebo in reducing MACE. There is increasing evidence that the use of SGLT2i may reduce the risk of stroke, particularly hemorrhagic stroke, in individuals with type 2 diabetes and a high risk of cardiovascular events, and that SGLT2i may also be beneficial for brain health by decreasing risk of cognitive decline and dementia. Antihyperglycemic therapy should be tailored to patients' circumstances. SGLT2i treatment should be considered in patients with type 2 diabetes and established or high-risk cardiovascular disease, heart failure, or chronic kidney disease, to reduce the overall cerebro-cardiovascular and renal risks.

321

News (Medical) associated with Empagliflozin

20 Aug 2025

·www.prnewswire.com

New Peer-Reviewed Study in New England Journal of Medicine Catalyst Finds Twin Health's AI Precision Treatment Significantly Improves Outcomes in Patients with Type 2 Diabetes and Reduces Reliance on Costly Medications, Including GLP-1s

Cleveland Clinic-led study finds Twin Health's precision AI and hyper-personalized care outperforms standard diabetes treatment—reducing A1C, unhealthy weight, and medication use MOUNTAIN VIEW, Calif., Aug. 20, 2025 /PRNewswire/ -- Today, Twin Health announced the publication of results from a Cleveland Clinic-led study in the New England Journal of Medicine Catalyst, evaluating its Twin Precision Treatment for the management of type 2 diabetes. The program features technology-driven interventions that leverage artificial intelligence to deliver personalized insights and lifestyle recommendations aimed at improving glycemic control and metabolic health in adults with type 2 diabetes. The findings, published today, showed that 71% of study participants using the Twin Precision Treatment system met the primary endpoint of achieving an A1C below 6.5% while eliminating most blood sugar-lowering medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and insulin. Continue Reading 71% of study participants in the Twin Health group lowered A1C below 6.5% without high-cost glucose-lowering medications. Type 2 diabetes affects nearly 1 in 10 Americans, and prolonged elevated blood sugar levels increase the risk of serious complications like heart disease, kidney failure, and stroke. Twin Precision Treatment System Uses Artificial Intelligence, Machine Learning and Wearable Sensors for Sustainable Results Developed by Twin Health, the Twin Precision Treatment combines digital twin AI with personalized clinical care, including licensed providers, nurses, and coaches. Using data from wearable sensors, the system continuously tracks real-time health metrics such as blood glucose levels, weight, blood pressure, stress, physical activity, and sleep. Users access these insights through a smartphone app, offering personalized nutrition and exercise guidance, encouraging patients to achieve their goals and sustainable health improvements. The specific app-generated dietary recommendations were based on AI-enabled predictions of each patient's blood glucose responses to specific meals. "The study demonstrates that AI-driven precision medicine is the key to metabolic healing," said Dr. Lisa Shah, chief medical officer and executive vice president of Twin Health. "We're committed to our mission of producing real results for real people. This study is an important milestone on that journey and a glimpse into what's ahead for the future of metabolic care." Kevin M. Pantalone, D.O., Director of Diabetes Initiatives at the Cleveland Clinic and a professor of medicine at the Cleveland Clinic Lerner College of Medicine, served as the primary investigator for this study. For the clinical trial (NCT05181449), researchers aimed to determine whether Twin Health's Twin Precision Treatment system could help individuals with type 2 diabetes, managed in a primary care setting, achieve their blood sugar goals while also eliminating glucose-lowering medications. "In routine clinical practice, type 2 diabetes is often treated with a one-size-fits-all approach where individuals are prescribed medications and told to 'watch their diet and stay active," said Dr. Pantalone. "Our study demonstrated the AI-enabled system of sensors to understand each patient's unique metabolic profile, and AI-enabled human care team coaching facilitated significant improvements in glycemic control, weight loss, and quality of life versus usual care, while allowing marked de-escalation of glucose-lowering medications. Interventions like this system can help patients make informed, lasting lifestyle changes to control their blood sugar and sustain weight loss." Dr. Pantalone collaborated with a team of 13 primary care physicians to recruit 150 patients from the Cleveland Clinic Twinsburg Family Health Center located in Twinsburg, Ohio. Of these, 100 were assigned to the Twin Precision Treatment group and 50 to the standard of care group. On average, patients were 58.5 years old, had been living with type 2 diabetes for about nine years, and presented with a mean body mass index (BMI) of 35.1 and an average A1C level of 7.2%. The primary endpoint was to see how many participants reached an A1C below 6.5% after 12 months without needing any glucose-lowering medications except for metformin, a common low-cost diabetes medication. After one year, a majority of study participants in the Twin intervention group achieved an A1C below 6.5% After one year, 71% of participants enrolled in the intervention group lowered their A1C levels below the 6.5% threshold, while taking only metformin. By comparison, only 2.4% of participants receiving standard care achieved the same result. Participants in the Twin intervention group also lost more weight (8.6% vs 4.6% of body weight) while significantly reducing their reliance on medications: GLP-1 Receptor Agonist medication use decreased from 41% to 6% among participants SGLT-2 Inhibitor use decreased from 27% to 1% of participants Dipeptidyl peptidase-4 (DPP-4) inhibitor use decreased from 33% to 3% in participants Insulin use decreased from 24% to 13% among participants The quality of life scores and treatment satisfaction were notably better for those using the Twin Precision Treatment, highlighting its potential as a highly effective and sustainable option for diabetes management. Real-World Reduction in GLP-1 Use In the Cleveland Clinic-led study, 85% of participants in the Twin Health program eliminated GLP-1s, demonstrating that many individuals can sustain clinical goals without long-term dependence. Translating Clinical Success into Cost Savings Twin Health is proven effective for diabetes, weight loss and metabolic health comorbidities, including hypertension. Twin Health's real-world results echo the RCT findings, delivering over $8,000 in average first-year savings per member. These savings result from reducing reliance on high-cost medications, such as GLP-1s, and avoiding unnecessary care utilization, making Twin a scalable and cost-effective solution for employers and health plans seeking to address the growing burden of metabolic disease. About Twin Health Twin Health's AI digital twin technology creates a real-time model of each individual's unique metabolism using data from smart devices, lab results, and meal logs. This model provides personalized guidance on nutrition, activity, sleep, and more, supported by a compassionate clinical team. Twin's AI digital twin and human care work in synergy, providing a continuous new standard of care for metabolic health. For employers and health plans, Twin delivers $8.0K+ in annualized savings per member by safely reducing reliance on high-cost medications and lowering avoidable medical utilization. Twin's clinical results for diabetes, weight loss and metabolic health co-morbidities, including hypertension, are peer-reviewed and published in top journals, including the New England Journal of Medicine Catalyst and those of the American Heart Association, American Diabetes Association, and American College of Cardiology. Learn more at . Press Contact Alex McKechnie AOX3 for Twin Health [email protected] 475.399.4056 SOURCE Twin Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultAHA

04 Aug 2025

·pharma.economictimes.indiatimes.com

NPPA sets retail prices of 37 drugs; notifies 4 scheduled formulations ceiling price

New Delhi: India’s drug price controller, NPPA has fixed the retail prices of 37 new drug including key type-2 diabetes formulations, antibiotics, cardiac therapies among several others. Issuing a gazette notification, the National Pharmaceutical Pricing Authority (NPPA) announced that the based on the decision of the 135th Authority meeting, the body has fixed retail prices of 37 formulations under Drugs (Prices Control) Order, 2013.” The notified list of 37 formulations includes key diabetes formulations of Empagliflozin, Sitagliptin, Meformin and Linagliptin. Additionally the list comprises formulation of Atorvastatin & Ezetimibe indicated for the treatment of high cholesterol and fats. The list further lunches other common anti-inflammatory formulations and drugs like Paracetamol, Diclofenac among several others. Under the Drugs Price Control Order any marketer, or manufacturers that intends to market a new drug in India is required to obtain a prior approval of the particular drug retail price from the NPPA and in case the fixed price is not complied, then the concerned manufacturer/marketing company is required to deposit the overcharged amount along with an interests per the relevant provision. However, the fixed retail prices are applicable only to the individual manufacturer / marketer who have applied for the same and are specified in the mentioned in the notified list. Meanwhile, in a separate gazette notification the national drug price controller has fixed the ceiling price of four scheduled formulations. The latest notified list includes Ipratropium, Sodium nitroprusside, Povidone iodine, and Diltiazem. Ipratropium is a ‘respirator solution’ indicated for the treatment of condictions like COPD and the drug ceiling price is capped at ₹2.96 per unit. Sodium nitroprusside is an injectable used to control high blood pressure and ceiling price of the formulation is fixed at ₹28.99. The other two scheduled formulations Povidone iodine and Diltiazem are used to treat skin infections and angina (severe chest pain), and the their ceiling price is fixed at ₹6.26 per ml and ₹26.72 per capsule respectively. According to the Ministry of Health and Family Welfare , the National list of Essential Medicines includes those formulations which are indicated for the treatment of diseases which is a public health problem in India, recommended under National Health Programs of India and several other factors. The prices of drugs categorised in the list are fixed and maintained by the NPPA to ensure the affordability of essential drugs for consumers and currently the list includes over 900 formulations. By Online Bureau ,

NDA

30 Jul 2025

·www.pharmaceutical-technology.com

Farxiga and Jardiance pose affordability issues, says Maryland drug board

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability challenges for the residents of Maryland. Credit: Robert Kneschke/Shutterstock.com Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) carry affordability challenges to the state’s residents, in a meeting on 28 July. These resolutions will now kickstart a process whereby the board will consider policy measures to address the affordability issues with these drugs, including one to set up an upper payment limit (UPL), which the pharma industry and several lobbying groups have consistently opposed. PDABs have been set up in at least 10 states in the US, with similar proposed legislation in several states. These state boards are made up of experts in the field, with most including physicians, health economists, pharmacists, and others. Each state has taken a unique approach with the framework governing these bodies with a distinct mandate and scope. However, the main objective across these boards is the same—to review and address rising prescription drug prices through several measures. Prescription drug prices have been in the news following tariffs, an executive order on the Most Favored Nation (MFN) policy , and the negotiations under the Inflation Reduction Act (IRA) for Medicare Part B drugs. Amidst these polices on the federal level, the role of states in influencing drug prices is often underestimated, but is still likely to be key given historical precedence, and recent Medicaid cuts . The Maryland PDAB made significant strides in formalising this review process, culminating in the July 28 meeting, where the board members deliberated on information contained in dossiers prepared for each drug. “The next step is we go into our policy review process,” Andrew York, Executive Director of the Maryland PDAB, tells Pharmaceutical Technology . Jardiance and Farxiga prices closely scrutinised After a drug is set to have an affordability challenge, the PDAB’s executive committee is tasked with finding the drivers behind those affordability challenges, and what policies the state can implement to address these, says York. Board meetings, like the latest Maryland PDAB, are usually livestreamed and are being closely followed by pharma companies, lobbyists, legal experts, patient advocacy organisations, and more. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence In the July 28 meeting, the board determined Farxiga had an ‘affordability challenge’ because the percentage change of its wholesale acquisition cost (WAC) over time was substantially higher than the rate of inflation; in certain cases, patient out-of-pocket costs were disproportionate to the net costs by the payers; and the total gross spending for Farxiga for state and local markets exceeded 1% of prescription drug spend for state and local governments. AstraZeneca did not respond to this news service for a comment, but in a July 5 letter to the board, an AstraZeneca spokesperson said that Farxiga accounts for only a fraction of the state’s spending—$20–30 million—while Maryland spends $6 billion on diabetes care. The spokesperson said the drug’s cost analysis does not take into account the burden of chronic kidney disease and heart failure, and the therapy’s impact in treating those conditions. In Jardiance’s case, the board said the drug presented an affordability challenge due to similar reasons, with the proportion of total gross spending for Jardiance by state and local governments exceeding 1.8% of gross spending for the state and local governments. Boehringer said the PDAB’s analysis using total gross spending did not represent out-of-pocket costs, or discounts and rebates that influence the final cost of a drug to a patient, in a July 9 letter. In 2024, Jardiance earned EUR8.4 billion ($8.8 billion), while Farxiga sales touched $7.7 billion. As part of the board proceedings being public, the cost review analysis made public includes information on each drug’s commercial and Medicaid utilization spending, its Medicare negotiated price, and more. Opinions divided on approach to improve access Chief among the concerns from pharma companies with PDABs is any measure to set a UPL on the drugs. On the subject of UPLs, York says, “That’s probably the thing that we’re most famous for. But right now, I think our board looks at it like it is a tool in the toolbox.” Throughout the public comment process, several patient advocates have expressed concerns that a UPL may deter companies from making their drugs available in a certain state. However, Peter Maybarduk, who directs the nonprofit Public Citizen’s access to medicines group, says this concern should not deter any review of drug prices. “Companies are responsible to shareholders. It [discontinuing access] would be extreme stance, especially if patients are outraged,” he says. Apart from Jardiance and Farxiga, both most commonly prescribed to patients with diabetes and cardiovascular issues, four other drugs have been chosen to be part of the drug review process—Novo Nordisk’s Ozempic (semaglutide), Eli Lilly’s Trulicity, AstraZeneca’s Dupixent (dupilumab), and AbbVie’s Skyrizi (risankizumab). York says the policy review for multiple drugs is likely to take place in parallel depending on whether they are said to present affordability challenges. The next meeting for the Maryland PDAB is scheduled for 15 September, 2025. This story is part of a reporting fellowship sponsored by the Association of Health Care Journalists and supported by The Commonwealth Fund. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

100 Deals associated with Empagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D10459	Empagliflozin	A10BK03	DB09038

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	China	Boehringer Ingelheim GmbH	26 May 2023
Cardiovascular Diseases	China	Boehringer Ingelheim International GmbH	26 May 2023
Heart failure with normal ejection fraction	China	Boehringer Ingelheim International GmbH	30 Aug 2022
Heart failure with normal ejection fraction	China	Boehringer Ingelheim (China) Investment Co., Ltd.	30 Aug 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim GmbH	10 Jun 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim International GmbH	10 Jun 2022
Chronic heart failure	European Union	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Iceland	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Liechtenstein	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Norway	Boehringer Ingelheim International GmbH	22 May 2014
Chronic Kidney Diseases	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Diabetes Mellitus, Type 2	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Heart Failure	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Defects, Congenital	Phase 3	Canada	Boehringer Ingelheim GmbH	01 May 2025
Glycosuria, Renal	Phase 3	-	Tanta University	01 Jan 2023
Schizophrenia	Phase 3	-	Tanta University	01 Jan 2023
Nonalcoholic Steatohepatitis	Phase 3	Egypt	Tanta University	01 Nov 2022
Hypoglycemia	Phase 3	Switzerland	Boehringer Ingelheim GmbH	11 Mar 2022
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim Pharma GmbH & Co., KG	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim International GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Eli Lilly & Co.	16 Dec 2020
Acute myocardial infarction	Phase 3	China	Boehringer Ingelheim GmbH	16 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03594110 (EMPA-KIDNEY, Pubmed \| EClinicalMedicine)	Phase 3	Chronic Kidney Diseases	6,609	Empagliflozin 10 mg	rbwcrwrhso(eowuhoospz) = stdexsdkrr pnvnqildno (gvurxuphoe )	Positive	01 Jul 2025
NCT05262764 (Pubmed \| Expert Opin Drug Saf)	Not Applicable	Heart Failure type 2 diabetes	-	Empagliflozin	sgujfodcpj(rsvtxemflu) = rfvnhoziiv dhwxfrlste (vwfczfcrsg ) View more	Positive	18 Jun 2025
NCT03753087 (Pubmed \| Cardiovasc Diabetol)	Phase 4	Diabetes Mellitus, Type 2 \| Heart failure with normal ejection fraction N-terminal pro-brain natriuretic peptide (NT-proBNP) \| sST2	70	Empagliflozin 10 mg	qcecjninoh(qikifdkeni) = zugwaojpnk btkbtukskq (vcbmrkqeyn )	Positive	09 May 2025
				empagliflozin (Control Group)	qcecjninoh(qikifdkeni) = smuhutidca btkbtukskq (vcbmrkqeyn )
NCT05282121 (CTgov)	Phase 2	Hepatitis A \| Esophageal and Gastric Varices \| Nonalcoholic Steatohepatitis ... View more	90	Avenciguat (Patients With HBV - Avenciguat)	tuhpeemeds(tmvwfitpaa) = aifrhmtatf jpgjuvmiuo (mhqzkrurkf, 6.66) View more	-	29 Apr 2025
				Avenciguat (Patients With HCV - Avenciguat)	tuhpeemeds(tmvwfitpaa) = qonlcvclxr jpgjuvmiuo (mhqzkrurkf, 7.09) View more
NCT03485092 (SUGAR-DM-HF, Pubmed \| Eur J Heart Fail)	Phase 4	Heart failure with reduced ejection fraction	105	Empagliflozin 10 mg	jtqadyotek(lmuhawomfa) = ejvcylaqzc gojxejzlwk (jymdtehupo, 2.5)	Positive	10 Jan 2025
				Placebo	-
NCT04509674 (EMPACT-MI, CTgov)	Phase 3	Heart Failure \| Acute myocardial infarction	6,522	Placebo (Placebo)	tswrvutucr = vnvrlmunos vtmmrqrqjl (sxzjlhyorp, fcwlpfbbap - wofhffuybu) View more	-	07 Jan 2025
				Empagliflozin (Empagliflozin 10 mg)	tswrvutucr = hsqyuiyvbf vtmmrqrqjl (sxzjlhyorp, opdeuobwij - ldvhrgcyxp) View more
NCT03594110 (EMPA-KIDNEY, Pubmed \| N Engl J Med)	Phase 3	Chronic Kidney Diseases estimated glomerular filtration rate (eGFR) \| urinary albumin-to-creatinine ratio	6,609	Empagliflozin 10 mg	wriyyzmhnf(azuwesyded) = ousabcwoao ihfaipwrqf (wrqjusflmj ) View more	Positive	25 Oct 2024
				Placebo	wriyyzmhnf(azuwesyded) = ijaxhyqmnt ihfaipwrqf (wrqjusflmj ) View more
NCT03087773 (EMMY, Pubmed \| Clin Res Cardiol)	Phase 3	Myocardial Infarction	313	Empagliflozin	tvomuwihlw(kdmgxtmowl) = parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort wimvqrdsnx (figezvkgfc ) View more	Positive	16 Sep 2024
				Placebo
NCT04509674 (EMPACT-MI, NEWS) Manual	Phase 3	Acute myocardial infarction	-	Empagliflozin	psxisrdogc(xjumduysxq) = zhggvjvbzv citckvwpfa (ppiwewmifm )	Positive	09 Sep 2024
				Placebo	psxisrdogc(xjumduysxq) = sqylkrruii citckvwpfa (ppiwewmifm )
ESC2024	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Heart Failure	-	Empagliflozin	rclszkccjb(rgqrgkgmpc) = jekxtnesxr kokdmbjgow (gcaizxoccy ) View more	-	31 Aug 2024
				Placebo	rclszkccjb(rgqrgkgmpc) = ejbcoooxyv kokdmbjgow (gcaizxoccy ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis